New onset diabetes predicts clinical outcomes in patients with pancreatic adenocarcinoma.

ABSTRACT:

Background

One percent of pancreatic adenocarcinoma (PDAC) patients are diagnosed with new onset diabetes (NOD) over the age of 50 years within 3 years. Therefore, NOD is a major factor for early diagnosis of PDAC. Research has focused on understanding the differences between NOD and type 2 diabetes, particularly in relation to PDAC. However, conflicting data exists regarding their impact on survival outcomes in PDAC patients. We performed this multi-center study to assess the prevalence and influence of NOD on clinical outcomes in patients with PDAC within a community-based hospital system.

Methods

We conducted a retrospective cohort study of 138 patients with biopsy-proven PDAC with localized/borderline disease (n=70), and metastatic disease (n=68) at three institutions fr

SUBMITTER: Mohindroo C 

PROVIDER: S-EPMC11921277 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature